T-Cell Coculture Potency Assays for Streamlined TIL Manufacturing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current TIL manufacturing and treatment processes are limited by length, cost, and sterility concerns, and there is a need for improved quality control methods to enhance the potency and functionality of T cells for treating refractory cancers.

Innovation Solution

A method for assessing T cell potency through co-culture with target and negative control cells, evaluating marker expression and analyte secretion, and a streamlined manufacturing process for TILs, including expansions with IL-2 and APCs, followed by cryopreservation for therapeutic use.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If traditional TIL manufacturing processes are used, then T cell expansion is achieved, but the process length and cost increase

Engineering Contradiction:

ImproveT cell expansionVSAvoidprocess length

Core Design Contradiction:

Quantity of substanceVSLoss of time

Solution Approach 1:

The patent applies preliminary action by pre-characterizing TIL samples for potency and functionality before full-scale expansion. This allows for early identification of high-potency TILs that are most likely to succeed in therapy, enabling streamlined manufacturing processes that focus resources on the most promising samples rather than processing all TIL expansions through the complete traditional protocol.

Inventive Principle:

Principle #10Preliminary action

2Quantity of substance

If traditional TIL manufacturing processes are used, then T cell expansion is achieved, but manufacturing cost increases

Engineering Contradiction:

ImproveT cell expansionVSAvoidmanufacturing cost

Core Design Contradiction:

Quantity of substanceVSEase of manufacture

Solution Approach 1:

The patent implements preliminary characterization assays that can be performed early in the manufacturing process to identify TIL samples with high therapeutic potential. This allows the manufacturing process to be streamlined by focusing full expansion and processing only on samples that demonstrate potency and functionality in these preliminary assessments, thereby reducing overall manufacturing costs by avoiding investment in expanding lower-potency samples.

Inventive Principle:

Principle #10Preliminary action

3Reliability

If TIL potency assessment is performed, then therapeutic efficacy is enhanced, but additional manufacturing steps are required

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidmanufacturing process complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies universality by developing potency and functionality assessment methods that can be integrated into existing TIL manufacturing workflows. The characterization assays are designed to use reagents and protocols that are compatible with standard manufacturing processes, allowing the same cellular products to be evaluated for potency while maintaining their therapeutic utility, thereby avoiding the need for separate parallel processes.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS12553031B2Methods and compositions for T-cell coculture potency assays and use with cell therapy products

Publication Date: 2026.02.17 IOVANCE BIOTHERAPEUTICS INC

AI summary

The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and/or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and/or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products. Compositions, methods, and kits for preparing and treating cancer using TIL, MIL, and PBL products are also provided.